Pancake Oral Immunotherapy For Egg Allergy In Inducing Tolerance

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions
Egg Allergy
Interventions
OTHER

Pancake oral immunotherapy

The baked egg tolerant group underwent a 4-dose initial escalation (at intervals of 20-30 minutes) with pancakes in hospital (37.5 mg, 75 mg, 150 mg, 300 mg egg protein) to determine the home starting dose of pancake. The dose tolerated was one which resulted in no more than mild transient (not lasting more than 20 minutes) symptoms (e.g. itchy mouth) - transient Grade 1 symptoms. The home starting dose (taken daily at home) was one step below the tolerated dose, to minimise risk of allergic reactions at home, particularly as the presence of co-factors might decrease reaction threshold. Those reacting at 37.5 mg or 75 mg would not begin OIT with pancakes but instead began with cookies. Updosing visits were performed in the hospital at approximately 4 weekly intervals. Participants were kept at the pancake daily maintenance dose (2500 mg) for a minimum of 16 weeks, or total OIT duration of 18 months, whichever earlier

Trial Locations (1)

Unknown

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
lead

KK Women's and Children's Hospital

OTHER_GOV

NCT07192510 - Pancake Oral Immunotherapy For Egg Allergy In Inducing Tolerance | Biotech Hunter | Biotech Hunter